Recipharm opens new GMP suite for clinical trial material
Recipharm, the contract development and manufacturing organisation (CDMO), has opened a newly built GMP suite for clinical trial material (CTM) manufacture at its facility in Research Triangle Park, North Carolina, USA.
The suite, which represents a $750k investment, is intended to produce CTM for clinical studies up to Phase II for non-sterile dosage forms, including metered dose inhalers and semi-solid topical products.
With the introduction of the GMP suite, Recipharm can now provide complete early development services from its facility in Research Triangle Park, including process development and scale-up, CTM manufacturing and packaging, product release and stability programs.
Ann Flodin, VP and General Manager of Recipharm’s facility in Research Triangle Park says “At Recipharm, we are focused on managing complexity for our customers and this means providing a full service offering to simplify the supply chain. Bolstering our development business is a key priority and with this investment, we are now able to offer our customers in the US a broader range of services and help them take their projects to the clinical phase in an efficient way. The new suite also meets an industry-wide demand for cGMP manufacturing space for orally inhaled drug products.”
The new GMP suite is ISO 8 certified and includes a walk-in downflow booth. The facility has the capacity to produce metered dose inhalers in up to 25L batches and offers semi-solid production capabilities up to 20L.
Recipharm is a leading global pharmaceutical CDMO. The development site in Research Triangle Park is part of the growing development services offering within Recipharm. From facilities across the world, Recipharm provides diversified formulation development and analytical services as well as CTM manufacture and access to a range of proprietary technologies and intellectual property.
For media enquiries, please contact Lindsay Baldry at ramarketing: firstname.lastname@example.org , + 44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /remarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00